参考文献 (References)[1] J. A. Hutcheon, S. Lisonkova and K. S. Joseph. Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. Best Practice & Research Clinical Obstetrics and Gynaecology, 2011, 25(4): 391-403.
[2] M. Hanssens, M. J. Keirse, B. Spitz and F. A. Van Assche. Measurement of individual plasma Angiotensins in normal pregnaney and pregnaney-indueed hypertension. Journal of Clinical Endocrinology and Metabolism, 1991, 73(3): 489-494.
[3] H. Haller, E. M. Ziegler, V. Homuth, J. Eiehhom, Z. Nagy and F. C. Luft. Endothelial adhesion molecules and leukoeyte integrins in preeclamptic patients. Hypertension, 1997, 29(1 pt 2): 291- 296.
[4] H. Haller, A. Hempel, V. Homuth, A. Mandelkow, C. Maaseh, M. Drab, et al. Endothelial cell permeability and protein kinase C in preeclampsia. Lancet, 1998, 351(9107): 945-949.
[5] G. Wallukat, V. Homuth, T. Fisher, C. Lindsehau, P. B. Horstkam, A. Jupner, et al. Patients with Preeclampsia develop agonistic autoantibodies against the Angiotensin AT1 receptor. Journal of Clinical Investigation, 1999, 103(7): 945-952.
[6] C. A. Hubel. Oxidative stress in the pathogenesis of preeclampsia. Proceedings of the Society for Experimental Biology and Medicine, 1999, 222(3): 222-235.
[7] R. Dechend, C. Viedt, D. N. Muller, B. Ugele, J. Theuer, A. Fiebeler, et al. AT1 receptor agonistic antibodies from preeclamptic patients stimulate NADPH oxidase. Circulation, 2003, 107(12): 1632-1639.
[8] A. Estellés, J. Gilabert, S. Grancha, K. Yamamoto, T. Thinnes, F. España, et al. Abnormal expression of type 1 plasminogen activator inhibitor and tissue factor in severe preeclampsia. Journal of Thrombosis and Haemostasis, 1998, 79(3): 500-508.
[9] R. Dechend, V. Homuth, G. Wallukat, J. Kleuzer, J. K. Park, J. Theuer, et al. AT(l) receptor agonistic antibodies from preeclamptic patient cause vascular cells to express tissue factor. Circulation, 2000, 101(20): 2382-2387.
[10] Y. Xia, H. Y. Wen and R. E. Kellems. Angiotensin II inhibits human trophoblast invasion through AT1 receptor activation. The Journal of Biological Chemistry, 2002, 277(27): 24601- 24608.
[11] Y. Xia, H. Wen, S. Bobst, M. C. Day and R. E. Kellems. Matemal autoantibodies from Preeclamptic patients activate Angiotensin receptors on human trophoblast cells. Journal of the Society for Gynecologic Investigation, 2003, 10(2): 82-93.
[12] S. M. Bobst, M. C. Day, L. C. Gilstrap, Y. Xia and R. E. Kellems. Maternal autoantibodies from preeclamptic patients activate Angiotensin receptors on human mesangial cells and induce interleukin-6 and plasminogen activator inhibitor-1 secretion. American Journal of Hypertension, 2005, 18(3): 330-336.
[13] A. Ahmed. Heparin-binding angiogenic growth factors in pregnancy. Trophoblast Research, 1997, 10: 215-258.
[14] T. Nagamatsu, T. Fujii, M. Kusumi, L. Zou, T. Yamashita, Y. Osuga, et al. Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: An implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology, 2004, 145(11): 4838-4845.
[15] S. Ahmad, A. Ahmed. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circulation Research, 2004, 95(9): 884-891.
[16] Y. Zhou, M. McMaster, K. Woo, M. Janatpour, J. Perry, T. Karpanen, et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. American Journal of Pathology, 2002, 160(4): 1405-1423.
[17] G. C. McKeeman, J. E. Ardill, C. M. Caldwell, A. J. Hunter and N. McClure. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. American Journal of Obstetrics & Gynecology, 2004, 191(4): 1240-1246.
[18] E. D. Dimitrakova, J. D. Dimitrakov, S. A. Karumanchi, B. K. Pehlivanov, N. P. Milchev and D. I. Dimitrakov. Placental soluble fms-like tyrosine-kinase-1 (sFlt-1) in pregnant women with preeclampsia. Folia Medica (Plovdiv), 2004, 46(1): 19-21.
[19] S. E. Maynard, J. Y. Min, J. Merchan, K. H. Lim, J. Li, S. Mondal, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. Journal of Clinical Investigation, 2003, 111(5): 649-658.
[20] R. J. Levine, R. Thadhani, C. Qian, C. Lam, K. H. Lim, K. F. Yu, et al. Urinary placental growth factor and risk of preeclampsia. Journal of the American Medical Association, 2005, 293(1): 77- 85.
[21] R. J. Levine, S. E. Maynard, C. Qian and K. H. Lim. Circulating Angiogenic factors and the risk of preeclampsia. The New England Journal of Medicine, 2004, 350(7): 672-683.
[22] K. Koga, Y. Osuga, O. Yoshino, Y. Hirota, X. Ruimeng, T. Hirata, et al. Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia. The Journal of Clinical Endocrinology & Metabolism, 2003, 88(5): 2348-2351.
[23] C. C. Zhou, S. Ahmad, T. Mi, L. Xia, S. Abbasi, P. W. Hewett, et al. Angiotensin II Induces soluble fms-like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy. Circulation Research, 2007, 100(1): 88-95.
[24] C. C. Zhou, Y. Zhang, R. A. Irani, H. Zhang, T. Mi, E. J. Popek, et al. Angiotensin receptor agonistic autoantibodies induce preeclampsia in pregnant mice. Nature Medicine, 2008, 14(8): 855- 862.
[25] R. A. Irani, Y. Zhang, C. C. Zhou, S. C. Blackwell, M. J. Hicks, S. M. Ramin, et al. Autoantibody-mediated angiotensin receptor activation contributes to preeclampsia through tumor necrosis factor-α signaling. Hypertension, 2010, 55(5): 1246-1253.